MX346144B - Porcion activadora del modulador farmacocinetico del agregado de galactosa para arnsi. - Google Patents

Porcion activadora del modulador farmacocinetico del agregado de galactosa para arnsi.

Info

Publication number
MX346144B
MX346144B MX2013006748A MX2013006748A MX346144B MX 346144 B MX346144 B MX 346144B MX 2013006748 A MX2013006748 A MX 2013006748A MX 2013006748 A MX2013006748 A MX 2013006748A MX 346144 B MX346144 B MX 346144B
Authority
MX
Mexico
Prior art keywords
vivo
data store
targeting
pharmacokinetic modulator
polynucleotides
Prior art date
Application number
MX2013006748A
Other languages
English (en)
Other versions
MX2013006748A (es
Inventor
L Lewis David
A Kitas Eric
B Rozema David
H Wakefield Darren
Mohr Peter
Hadwiger Philipp
Hoffmann Torsten
Roehl Ingo
Valis Linda
Original Assignee
Arrowhead Res Corp *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arrowhead Res Corp * filed Critical Arrowhead Res Corp *
Publication of MX2013006748A publication Critical patent/MX2013006748A/es
Publication of MX346144B publication Critical patent/MX346144B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a composiciones para el suministro activado de polinucleátidos de interferencia de ARN (iARN) a células in vivo. El modulador farmacocinético mejora la activación in vivo comparado con el ligado activador solo. El ligando activador y la porción activante del modulador activador que activan los polinucleátidos de iARN pueden administrarse in vivo solos o en combinación con polímeros de suministro co-activados.
MX2013006748A 2010-12-17 2011-12-15 Porcion activadora del modulador farmacocinetico del agregado de galactosa para arnsi. MX346144B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061424195P 2010-12-17 2010-12-17
PCT/US2011/065210 WO2012083046A2 (en) 2010-12-17 2011-12-15 Galactose cluster-pharmacokinetic modulator targeting moiety for sirna

Publications (2)

Publication Number Publication Date
MX2013006748A MX2013006748A (es) 2013-07-17
MX346144B true MX346144B (es) 2017-03-09

Family

ID=46235176

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006748A MX346144B (es) 2010-12-17 2011-12-15 Porcion activadora del modulador farmacocinetico del agregado de galactosa para arnsi.

Country Status (12)

Country Link
US (2) US9249179B2 (es)
EP (2) EP3192800A1 (es)
JP (2) JP2014504295A (es)
KR (1) KR20130132475A (es)
CN (1) CN103492568B (es)
AU (2) AU2011343664B2 (es)
BR (1) BR112013013434A2 (es)
CA (1) CA2816155C (es)
MX (1) MX346144B (es)
RU (1) RU2013117288A (es)
SG (1) SG189474A1 (es)
WO (1) WO2012083046A2 (es)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080281041A1 (en) * 1999-06-07 2008-11-13 Rozema David B Reversibly Masked Polymers
AU2011343664B2 (en) * 2010-12-17 2015-10-08 Arrowhead Pharmaceuticals, Inc. Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA
BR122020024388B1 (pt) * 2010-12-29 2021-09-21 F. Hoffmann-La Roche Ag Oligonucleotídeo e composição farmacêutica
EP3453761A1 (en) 2011-08-29 2019-03-13 Ionis Pharmaceuticals, Inc. Oligomer-conjugate complexes and their use
KR20150001710A (ko) 2012-04-18 2015-01-06 애로우헤드 리서치 코오포레이션 Ｉｎ Ｖｉｖｏ 핵산 전달용 폴리(아크릴레이트) 고분자
EP2838544A4 (en) * 2012-04-18 2015-10-14 Arrowhead Res Corp POLY (ACRYLATE) POLYMERS FOR IN VIVO NUCLEIC ACID ADMINISTRATION
DK2920307T3 (en) 2012-11-15 2018-07-16 Roche Innovation Ct Copenhagen As ANTI-APOB, ANTISENSE CONJUGATE RELATIONSHIPS
WO2014118272A1 (en) 2013-01-30 2014-08-07 Santaris Pharma A/S Antimir-122 oligonucleotide carbohydrate conjugates
DK2951305T3 (en) 2013-01-30 2018-10-29 Hoffmann La Roche LNA oligonucleotide KULHYDRATKONJUGATER
JP2016511256A (ja) 2013-02-28 2016-04-14 アローヘッド リサーチ コーポレイション Ｅｐａｓ１関連疾患を治療するための有機組成物
KR20160002977A (ko) 2013-05-01 2016-01-08 아이시스 파마수티컬즈 인코포레이티드 조성물 및 방법
EP2992095B1 (en) 2013-05-01 2019-01-09 Regulus Therapeutics Inc. Microrna compounds and methods for modulating mir-122
JP6649248B2 (ja) 2013-05-01 2020-02-19 レグルス セラピューティクス インコーポレイテッド 細胞取り込みの向上のための化合物および方法
EP3003288A1 (en) 2013-05-30 2016-04-13 Nanobiotix Pharmaceutical composition, preparation and uses thereof
HUE048738T2 (hu) * 2013-06-27 2020-08-28 Roche Innovation Ct Copenhagen As Antiszensz oligomerek és konjugátumok, amelyek a PCK9-t célozzák meg
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
WO2015061536A1 (en) 2013-10-25 2015-04-30 Regulus Therapeutics Inc. Microrna compounds and methods for modulating mir-21 activity
CN105722980A (zh) * 2013-11-14 2016-06-29 罗氏创新中心哥本哈根有限公司 Apob反义缀合物化合物
WO2015105083A1 (ja) * 2014-01-07 2015-07-16 塩野義製薬株式会社 アンチセンスオリゴヌクレオチド及び糖誘導体を含む二本鎖オリゴヌクレオチド
EP3647318B1 (en) 2014-04-28 2021-06-30 Ionis Pharmaceuticals, Inc. Linkage modified oligomeric compounds
JP2017521045A (ja) 2014-05-01 2017-08-03 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． アンジオポエチン様因子３発現を調節するための組成物及び方法
CN110724687B (zh) 2014-05-01 2023-10-13 Ionis制药公司 用于调节补体因子b表达的组合物和方法
RU2724527C2 (ru) 2014-05-01 2020-06-23 Ионис Фармасьютикалз, Инк. Композиции и способы модулирования экспрессии рецептора гормона роста
AU2015252917B2 (en) 2014-05-01 2019-09-26 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating PKK expression
GB201408623D0 (en) 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
US10570169B2 (en) 2014-05-22 2020-02-25 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
TW201613949A (en) 2014-08-07 2016-04-16 Regulus Therapeutics Inc Targeting microRNAs for metabolic disorders
WO2016040748A1 (en) 2014-09-12 2016-03-17 Ionis Pharmaceuticals, Inc. Compositions and methods for detection of smn protein in a subject and treatment of a subject
BR112017005938A2 (pt) 2014-10-10 2017-12-12 Hoffmann La Roche compostos, processo de preparação de composto, processo de preparação de conjugado de galnac e ácido nucleico e usos de composto
PT3223796T (pt) * 2014-11-25 2021-09-28 Curadigm Sas Composições farmacêuticas, preparação e suas utilizações
LT3229776T (lt) 2014-11-25 2023-08-25 Curadigm Sas Farmacinė kompozicija, kurioje derinamos mažiausiai dvi skirtingos nanodalelės ir farmacinis mišinys, jos paruošimas ir vartojimas
WO2016161388A1 (en) 2015-04-03 2016-10-06 University Of Massachusetts Fully stabilized asymmetric sirna
EA201792103A1 (ru) 2015-05-29 2018-06-29 Эрроухэд Фармасьютикалз, Инк. Композиции и способы для ингибирования экспрессии генов hif2альфа
IL316159A (en) 2015-06-15 2024-12-01 Mpeg La Llc Defined Oligonucleotide Multimers and Methods for Manufacture Thereof
US20180312845A1 (en) 2015-07-10 2018-11-01 Ionis Pharmaceuticals, Inc. Modulators of diacyglycerol acyltransferase 2 (dgat2)
JPWO2017010575A1 (ja) * 2015-07-16 2018-04-26 協和発酵キリン株式会社 β２ＧＰＩ遺伝子発現抑制核酸複合体
CN107709342B (zh) * 2015-08-06 2021-09-03 豪夫迈·罗氏有限公司 制备乙酰半乳糖胺酸衍生物的方法
WO2017030973A1 (en) 2015-08-14 2017-02-23 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
KR20180051626A (ko) 2015-09-24 2018-05-16 아이오니스 파마수티컬즈, 인코포레이티드 Kras 발현의 조절제
JOP20210043A1 (ar) * 2015-10-01 2017-06-16 Arrowhead Pharmaceuticals Inc تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
CN108136041B (zh) 2015-10-02 2022-12-30 罗氏创新中心哥本哈根有限公司 寡核苷酸缀合方法
WO2017067970A1 (en) 2015-10-22 2017-04-27 Roche Innovation Center Copenhagen A/S In vitro toxicity screening assay
US20190046555A1 (en) 2015-11-06 2019-02-14 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds for use in therapy
CA2999341A1 (en) 2015-11-06 2017-05-11 Ionis Pharmaceuticals, Inc. Modulating apolipoprotein (a) expression
BR112018003910B1 (pt) * 2015-11-16 2022-03-22 F. Hoffmann-La Roche Ag Derivado de fosforamidita galnac, processo para a preparação de um derivado de fosforamidita galnac de fórmula i e uso dos derivados de fosforamidita galnac de fórmula i
ES2858090T3 (es) 2016-01-29 2021-09-29 Kyowa Kirin Co Ltd Complejo de ácidos nucleicos
EP3408391A4 (en) 2016-01-31 2019-08-28 University of Massachusetts BRANCHED OLIGONUCLEOTIDES
CN109069529B (zh) 2016-03-07 2021-08-20 箭头药业股份有限公司 用于治疗性化合物的靶向配体
CN108779465B (zh) 2016-03-14 2022-05-13 豪夫迈·罗氏有限公司 用于减少pd-l1表达的寡核苷酸
MA45478A (fr) 2016-04-11 2019-02-20 Arbutus Biopharma Corp Compositions de conjugués d'acides nucléiques ciblés
EP3442983A1 (en) 2016-04-14 2019-02-20 H. Hoffnabb-La Roche Ag TRITYL-MONO-Ga1NAc COMPOUNDS AND THEIR USE
US11390867B2 (en) 2016-04-29 2022-07-19 Nanyang Technological University G-quadruplex-containing antisense oligonucleotides
WO2017216340A1 (en) 2016-06-17 2017-12-21 F. Hoffmann-La Roche Ag In vitro nephrotoxicity screening assay
CN109312403B (zh) 2016-06-17 2023-06-27 豪夫迈·罗氏有限公司 体外肾毒性筛选测定法
HUE060831T2 (hu) 2016-07-15 2023-04-28 Ionis Pharmaceuticals Inc Vegyületek és eljárások SMN2 modulálására
EP3496758A4 (en) 2016-08-12 2020-11-11 University of Massachusetts CONJUGATE OLIGONUCLEOTIDES
JOP20170056B1 (ar) * 2016-09-02 2021-08-17 Arrowhead Pharmaceuticals Inc مركبات ترابطية مستهدفة
WO2018067900A1 (en) 2016-10-06 2018-04-12 Ionis Pharmaceuticals, Inc. Method of conjugating oligomeric compounds
JOP20190215A1 (ar) 2017-03-24 2019-09-19 Ionis Pharmaceuticals Inc مُعدّلات التعبير الوراثي عن pcsk9
JP2020516296A (ja) 2017-04-11 2020-06-11 アルブータス・バイオファーマー・コーポレイション 標的化組成物
WO2018215049A1 (en) * 2017-05-23 2018-11-29 F. Hoffmann-La Roche Ag Process for galnac oligonucleotide conjugates
JP7406793B2 (ja) 2017-06-23 2023-12-28 ユニバーシティー オブ マサチューセッツ ２テイル自己デリバリー型ｓｉＲＮＡおよび関連方法
KR20200113214A (ko) 2018-01-15 2020-10-06 아이오니스 파마수티컬즈, 인코포레이티드 Dnm2 발현의 조절제
US20210095277A1 (en) 2018-01-18 2021-04-01 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting srebp1
AU2019218987B2 (en) 2018-02-12 2025-04-24 Ionis Pharmaceuticals, Inc. Modified compounds and uses thereof
US20220002796A1 (en) 2018-05-07 2022-01-06 Roche Innovation Center Copenhagen A/S Quality control of lna oligonucleotide therapeutics using massively parallel sequencing
JP7279081B2 (ja) 2018-05-08 2023-05-22 レグルス セラピューティクス インコーポレイテッド Ｍｉｒ－１２２を調節するためのマイクロｒｎａ化合物及び方法
BR112020020957B1 (pt) 2018-05-09 2022-05-10 Ionis Pharmaceuticals, Inc Compostos oligoméricos, população e composição farmacêutica dos mesmos e seus usos
EP3794030A4 (en) * 2018-05-17 2022-03-09 Housey Pharmaceutical Research Laboratories, L.L.C. INHIBITION OF FOLLISTATIN
WO2020007826A1 (en) 2018-07-05 2020-01-09 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting mbtps1
WO2020011744A2 (en) 2018-07-11 2020-01-16 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting cers5
WO2020011745A2 (en) 2018-07-11 2020-01-16 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting cers6
EP3823725A4 (en) 2018-07-17 2023-05-10 Aronora, Inc. METHODS FOR SAFELY REDUCING THROMBOPOIETIN
US20220098581A1 (en) 2018-07-20 2022-03-31 Regulus Therapeutics Inc. Methods for Oral Delivery of Oligonucleotides
EP3833397A4 (en) 2018-08-08 2023-06-14 Arcturus Therapeutics, Inc. COMPOSITIONS AND AGENTS AGAINST NON-ALCOHOLIC STEATOHEPATITIS
CA3109133A1 (en) 2018-08-10 2020-02-13 University Of Massachusetts Modified oligonucleotides targeting snps
EP3840759A4 (en) 2018-08-23 2022-06-01 University Of Massachusetts O-METHYL RICH FULLY STABILIZED OLIGONUCLEOTIDES
TWI856973B (zh) 2018-09-19 2024-10-01 美商Ionis製藥公司 Pnpla3表現之調節劑
AU2019376628B2 (en) * 2018-11-09 2025-08-07 Alnylam Pharmaceuticals, Inc. Modified double stranded oligonucleotides
AU2019403447B2 (en) 2018-12-21 2023-07-27 Ionis Pharmaceuticals, Inc. Modulators of HSD17B13 expression
CN113613661B (zh) 2019-01-09 2025-11-14 箭头药业股份有限公司 用于抑制HIF-2α(EPAS1)的表达的RNAi试剂、其组合物和使用方法
CA3125441A1 (en) 2019-01-18 2020-07-23 University Of Massachusetts Dynamic pharmacokinetic-modifying anchors
US11510939B1 (en) 2019-04-19 2022-11-29 Apellis Pharmaceuticals, Inc. RNAs for complement inhibition
EP4010476A4 (en) 2019-08-09 2023-12-27 University Of Massachusetts Chemically modified oligonucleotides targeting snps
US12365894B2 (en) 2019-09-16 2025-07-22 University Of Massachusetts Branched lipid conjugates of siRNA for specific tissue delivery
EP4045062A1 (en) 2019-10-14 2022-08-24 Astrazeneca AB Modulators of pnpla3 expression
CN111041025B (zh) 2019-12-17 2021-06-18 深圳市瑞吉生物科技有限公司 基于结合N-乙酰半乳糖胺多肽的mRNA靶向分子及其制备方法
WO2021146548A1 (en) * 2020-01-17 2021-07-22 Anastasia Khvorova Universal dynamic pharmacokinetic-modifying anchors
AR121446A1 (es) 2020-02-28 2022-06-08 Ionis Pharmaceuticals Inc Compuestos y métodos para modular smn2
IL297483A (en) 2020-04-21 2022-12-01 Flagship Pioneering Inc Bifunctional compounds and their uses
WO2021219077A1 (zh) * 2020-04-29 2021-11-04 泰比棣医药科技(石家庄)有限公司 一种组织靶向的蛋白靶向降解化合物及其用途
WO2021226454A1 (en) * 2020-05-08 2021-11-11 Mpeg La, L.L.C. Linker compounds
EP4157289A4 (en) 2020-05-26 2024-06-26 University Of Massachusetts Synthetic oligonucleotides having regions of block and cluster modifications
CN111744019B (zh) 2020-07-01 2023-08-04 深圳瑞吉生物科技有限公司 基于甘露糖的mRNA靶向递送系统及其应用
EP4488371A3 (en) 2020-11-18 2025-04-09 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating angiotensinogen expression
CR20230308A (es) 2020-12-11 2023-09-08 Civi Biopharma Inc Entrega oral de conjugados antisentido que tienen por blanco a pcsk9
CA3206285A1 (en) 2020-12-23 2022-06-30 Flagship Pioneering, Inc. Compositions of modified trems and uses thereof
TW202246500A (zh) * 2021-02-02 2022-12-01 瑞士商赫孚孟拉羅股份公司 用於抑制 ｒｔｅｌ１ 表現之增強型寡核苷酸
IL307885A (en) 2021-04-23 2023-12-01 Ganna Bio Inc Nucleic acids with different glycans, preparation methods and therapeutic uses
US12472148B2 (en) 2021-04-26 2025-11-18 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
WO2022234346A1 (en) * 2021-05-07 2022-11-10 Twinpig Biolab, Inc. Peptides targeting macrophages, and conjugates, compositions, and uses thereof
US11702659B2 (en) 2021-06-23 2023-07-18 University Of Massachusetts Optimized anti-FLT1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
CN113683673B (zh) * 2021-09-10 2023-06-20 重庆市畜牧科学院 一种基于蜂毒肽的脂肽及其制备方法和应用
AU2022357561A1 (en) 2021-10-01 2024-04-18 Adarx Pharmaceuticals, Inc. Prekallikrein-modulating compositions and methods of use thereof
EP4544043A1 (en) 2022-06-22 2025-04-30 Flagship Pioneering Innovations VI, LLC Compositions of modified trems and uses thereof
US20250388901A1 (en) 2022-12-19 2025-12-25 Arnatar Therapeutics, Inc. Advanced rna targeting (arnatar)
EP4444357B1 (en) 2022-12-19 2025-05-21 Arnatar Therapeutics, Inc Arnatar compounds and methods for enhanced cellular uptake
CN121285630A (zh) 2023-04-20 2026-01-06 阿达尔克斯制药有限公司 Mapt调节组合物及其使用方法
AU2024273075A1 (en) 2023-05-12 2025-11-20 Adarx Pharmaceuticals, Inc. Nmda ligand conjugated compounds and uses thereof
WO2024249328A2 (en) 2023-05-26 2024-12-05 Adarx Pharmaceuticals, Inc. Sod1-modulating compositions and methods of use thereof
EP4562158A1 (en) 2023-06-13 2025-06-04 Arnatar Therapeutics, Inc Advanced rna targeting (arnatar) for angiotensinogen
AU2024313301A1 (en) 2023-06-20 2025-12-11 Adarx Pharmaceuticals, Inc. Lrrk2-modulating compositions and methods of use thereof
US20250051771A1 (en) 2023-07-24 2025-02-13 Astrazeneca Ab Multivalent cargo-carrying complexes and uses thereof
GB202311334D0 (en) 2023-07-24 2023-09-06 Astrazeneca Ab Multivalent cargo-carrying complexes and uses thereof
GB202311324D0 (en) 2023-07-24 2023-09-06 Astrazeneca Ab Multivalent cargo-carrying complexes and uses thereof
EP4665854A1 (en) 2024-01-29 2025-12-24 Arnatar Therapeutics, Inc Translation enhancing nucleic acid compounds: aso coupled translation - upregulation 1 (act-up1) and uses thereof
WO2025165891A1 (en) 2024-01-29 2025-08-07 Arnatar Therapeutics, Inc Translation enhancing nucleic acid compounds: aso coupled translation - upregulation 1 (act-up1) and uses thereof
WO2025264546A1 (en) * 2024-06-18 2025-12-26 Sirius Therapeutics, Inc. Lipid-polynucleic acid conjugate compositions and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9201440A (nl) 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
US6300319B1 (en) 1998-06-16 2001-10-09 Isis Pharmaceuticals, Inc. Targeted oligonucleotide conjugates
US8541548B2 (en) * 1999-06-07 2013-09-24 Arrowhead Madison Inc. Compounds and methods for reversible modification of biologically active molecules
US7491805B2 (en) * 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US7833992B2 (en) * 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US7662952B2 (en) * 2002-02-20 2010-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acid (siNA)
US7816337B2 (en) 2003-02-18 2010-10-19 Roche Madison Inc. Reversible attachment of a membrane active polymer to a polynucleotide
BRPI0715375A2 (pt) * 2006-08-18 2013-06-18 Hoffmann La Roche policonjugados para distribuiÇço in vivo de polinucleotÍdeos
US20100144831A1 (en) * 2006-09-27 2010-06-10 Habib Fakhral Blocking of gene expression in eukaryotic cells
US20100015218A1 (en) 2007-02-16 2010-01-21 Vasant Jadhav Compositions and methods for potentiated activity of biologically active molecules
CA2930393C (en) * 2007-12-04 2022-11-29 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
WO2009120878A2 (en) * 2008-03-26 2009-10-01 Alnylam Pharmaceuticals, Inc. Non-natural ribonucleotides, and methods of use thereof
AU2009234266B2 (en) * 2008-04-11 2015-08-06 Tekmira Pharmaceuticals Corporation Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
AU2011219941C1 (en) * 2010-02-24 2015-05-07 Arrowhead Pharmaceuticals, Inc. Compositions for targeted delivery of siRNA
AU2011343664B2 (en) * 2010-12-17 2015-10-08 Arrowhead Pharmaceuticals, Inc. Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA

Also Published As

Publication number Publication date
KR20130132475A (ko) 2013-12-04
JP2016185968A (ja) 2016-10-27
WO2012083046A2 (en) 2012-06-21
WO2012083046A3 (en) 2012-09-27
SG189474A1 (en) 2013-05-31
JP6261144B2 (ja) 2018-01-17
AU2016200000A1 (en) 2016-01-28
EP2652134A2 (en) 2013-10-23
US9796756B2 (en) 2017-10-24
AU2011343664A1 (en) 2013-05-09
AU2016200000B2 (en) 2018-01-04
MX2013006748A (es) 2013-07-17
CN103492568A (zh) 2014-01-01
JP2014504295A (ja) 2014-02-20
BR112013013434A2 (pt) 2016-08-16
EP3192800A1 (en) 2017-07-19
CN103492568B (zh) 2017-04-12
US20160102120A1 (en) 2016-04-14
CA2816155A1 (en) 2012-06-21
EP2652134A4 (en) 2014-05-21
CA2816155C (en) 2020-10-27
RU2013117288A (ru) 2015-01-27
EP2652134B1 (en) 2017-03-01
US9249179B2 (en) 2016-02-02
US20120157509A1 (en) 2012-06-21
AU2011343664B2 (en) 2015-10-08

Similar Documents

Publication Publication Date Title
MX346144B (es) Porcion activadora del modulador farmacocinetico del agregado de galactosa para arnsi.
PH12013501186A1 (en) Seed treatment facilities, methods, and apparatus
MX2009007663A (es) Dispositivo medico para el tratamiento de estenosis de pasajes corporales y para la prevencion de reestenosis inminente.
CN104812334B (zh) 批量疫苗接种设备
ZA201509053B (en) A system for variable-ratio blending of multiple agricultural products for delivery via a ported opener
ZA200808294B (en) A medical treatment material delivery apparatus
EP3826025A3 (en) Pharmaceutical packaging and method for delivery of same
NZ627896A (en) Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
AR105236A1 (es) Equipo y método para minimizar el volumen de un portador líquido utilizado para suministrar productos agrícolas en un surco durante la plantación
PH12014502025A1 (en) Rice transplanter-mounted liquid reagent application device, and method of applying liquid reagent during rice planting using same
WO2008112731A3 (en) Remote medication management system
WO2009012371A3 (en) Operation of a remote medication management system
FR2961192B1 (fr) Dispositif de distribution de produit comprenant une pompe et un embout de distribution
CL2010000023A1 (es) Sistema para suministrar aire a un grupo de celdas electroliticas que comprende; un soplador de aire, una tuberia de suministro, un flujometro con un regulador de flujo y conectado entre una primera manguera y una segunda manguera; y un proceso para la operacion de un sistema.
MX2013003457A (es) Sistemas y metodos para cebar o purgar un distribuidor de producto.
MY170597A (en) Liquid dispensing system for use in the formation of a tobacco pouch product
Dobson Cognitive therapy.
WO2013040196A3 (en) Automated device for biologic drug distribution
FR2955091B1 (fr) Dispositif de conditionnement et de distribution d'un produit, notamment d'un produit cosmetique, comprenant un tube plongeur.
WO2012170651A3 (en) Apparatus, system, and method for automated dispensing of a substance on one or more seeds
EP2724513A4 (en) COMMUNICATION METHOD IN A PATH CALCULATION ELEMENT, COMMUNICATION PROTOCOL AND NETWORK DEVICE
FR2942701B1 (fr) Dispositif de distribution d'un produit cosmetique, et procede de stockage associe
NZ727796A (en) Seed treatment facilities, methods, and apparatus
Yoshioka et al. Recent progress and prospect in oligonucleotide therapeutics
MX2015004340A (es) Proceso automatizado de distribucion de medicamentos en dosis unitaria.

Legal Events

Date Code Title Description
FG Grant or registration